• Hematological malignancies: malnutrition a significant threat to survival

    1 in 4 patients met criteria for malnourishment.

  • Pediatric AML: clofarabine regimen spares anthracyclines, maintains survival

    No significant difference in 3-year event-free survival and OS.

  • CLL: mode of progression after first-line therapy linked to outcomes

    Findings may inform future trial design.

  • Exercise may cut risk for myelodysplastic syndromes

    Moderate to vigorous physical activity may also reduce risk for other myeloid neoplasms.

  • EHA 2019 – Expert Commentary – Pregnancy and family planning: an evaluable option in patients with chronic myeloid leukemia

    In the tyrosine kinase inhibitors era, patients can safely plan pregnancy which in most cases results in labour when the right treatment and good compliance are applied

  • AML/MDS: lower-dose conditioning effective in older patients receiving CBT

    Regimen supported early recovery, high neutrophil engraftment.

  • EHA 2019 – Nelarabine in the real-world, an effective option for relapsed/refractory T-acute lymphoblastic leukaemia/lymphoma

    In one of the largest cohorts of adult patients with the disease, nelarabine led to good response rates and was shown effective in bridging patients to transplant

  • EHA 2019 – Gilteritinib, a new treatment paradigm for relapsed/refractory acute myeloid leukaemia

    The final results of the ADMIRAL trial highlight the value of gilteritinib monotherapy for adult patients harbouring FLT3-mutations

  • EHA 2019 – Acalabrutinib shows remarkable benefit in relapsed or refractory chronic lymphocytic leukaemia

    Promising results from the ad interim analysis of the ASCEND Study investigating acalabrutinib monotherapy were presented for the first time at EHA congress

  • EHA 2019 – Complex karyotype influences the response to therapy in treatment-naïve CLL patients with coexisting conditions

    A prospective analysis from the CLL14 trial supports the importance of chromosome examination and highlights the efficacy of VenG in patients harbouring complex karyotype

  • EHA 2019 – Outcomes after different intensity of conditioning in acute myeloid leukaemia: the importance of genomic variants

    The worse survival rates observed after reduced-intensity conditioning are limited to individuals with genomic evidence of residual disease prior to transplant.

  • CML-CP: can TKI deescalation foster improved treatment-free remission?

    Final data from the DESTINY study.

  • NCCN releases first guidelines for pediatric ALL

    Focus on novel regimens, supportive care to reduce adverse effects.

  • ASCO 2019 — Venetoclax+obinutuzumab extends PFS in frontline CLL

    Unprecedented high and durable MRD negativity in elderly patients with comorbidities.

  • Load more